2 NMO Patients Stay Relapse-Free for 15+ Years After Donor Stem-Cell Transplants
Updated
Updated · ScienceAlert · Jul 5
2 NMO Patients Stay Relapse-Free for 15+ Years After Donor Stem-Cell Transplants
1 articles · Updated · ScienceAlert · Jul 5
Summary
Two 28-year-old patients with aggressive, treatment-refractory neuromyelitis optica remained relapse-free for 15 and 16 years after allogeneic hematopoietic cell transplantation, with no ongoing immunosuppression and permanent disappearance of AQP4-IgG antibodies.
The procedure used donor blood stem cells after fludarabine and treosulfan chemotherapy wiped out the patients’ B cells, effectively rebuilding the immune system without the antibody-producing cells that attack astrocytes.
Both patients reported better quality of life: the man improved neurologically, resumed normal life and later fathered two children, while the woman regained some arm function and needed no further medication.
The treatment still carried serious risks—one patient developed chronic immune deficiency requiring antibody supplementation and the other developed surgically treated bladder cancer—though neither complication was proven transplant-related.
Researchers said this is the longest reported follow-up of alloHCT in NMO and argued the approach should be reserved for carefully selected younger patients until larger studies clarify safety and who might benefit most.
Two patients were cured 15 years ago. Why has this revolutionary but dangerous treatment not become more widespread?
Doctors cured an incurable disease by replacing the immune system. What other autoimmune disorders could this radical approach conquer next?
This 'cure' for a severe autoimmune disease led to cancer. Is trading one illness for another worth the risk?
Immune System Reset Achieves 15+ Years Remission in NMOSD: Breakthrough with Allogeneic HSCT
Overview
A groundbreaking medical advance has been reported in Neuromyelitis Optica Spectrum Disorder (NMOSD), a rare autoimmune disease that attacks the optic nerves and spinal cord, causing severe symptoms like vision loss and paralysis. For the first time, two patients received allogeneic hematopoietic stem cell transplants and have remained relapse-free for over 15 years. This success highlights the limitations of traditional immunosuppressive treatments, which often fail to prevent relapses and cause significant side effects. The long-term remission seen in these patients suggests that replacing the immune system could offer new hope for those with severe, treatment-resistant NMOSD.